Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 7, 2004, Pages 1156-1162

  Frankenfeld, Cara L ^a,b   McTiernan, Anne ^a,b   Aiello, Erin J ^a,c   Thomas, Wendy K ^a   LaCroix, Kristin ^a   Schramm, Judy ^a   Schwartz, Stephen M ^a,b   Holt, Victoria L ^a,b   Lampe, Johanna W ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; EQUOL; ESTRONE; FOLLITROPIN; O NORANGOLENSIN; SOYBEAN PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; BREAST CARCINOMA; CANCER RISK; CONTROLLED STUDY; ESTRONE BLOOD LEVEL; FAMILY HISTORY; FEMALE; FOLLITROPIN BLOOD LEVEL; GAS CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASS SPECTROMETRY; METABOLITE; OBESITY; PHENOTYPE; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN METABOLISM; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; URINE LEVEL;

AGED; BREAST; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; DIETARY SUPPLEMENTS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INTESTINES; ISOFLAVONES; MAMMOGRAPHY; MIDDLE AGED; OBESITY; PHENOTYPE; PHYTOESTROGENS; POSTMENOPAUSE; SOYBEAN PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 3142751399     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Saftlas AF, Hoover RN, Brinton LA, et al. Mammographic densities and risk of breast cancer. Cancer 1991;67:283o-8.
2. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87:670-5.
3. Byrne C, Schairer C, Brinton LA, et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes & Control 2001;12:103-10.
4. Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6.
5. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol, Biomarkers & Prev 1999;8:863-6.
6. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol, Biomarkers & Prev 2000;9:911-5.
7. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol, Biomarkers & Prev 2000;9:917-21.
8. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
9. Rutter CM, Mandelsor, MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285: 171-6.
10. Leung W, Goldberg F, Zee B, Stems E. Mammographic density in women on postmenopausal hormone replacement therapy. Surgery 1997;122:669-73.
11. White E, Velentgas MT, Lehman CD, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90:906-10.
12. Mishell DR Jr, Nakamura RM, Crosignani PG, et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol 1971;111:60-5.
13. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82.
14. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes & Control 2000;11:955-63.
15. Bergkvist L, Tabar L, Bergstrom R, Adami HO. Epidemiologic determinants of the mammographic parenchymal pattern. A population-based study within a mammographic screening program. Am J Epidemiol 1987;126:1075-81.
16. Gram IT, Funkhouser E, Tabar L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. Br J Cancer 1995;71:647-50.
17. Kaufman Z, Garstin WI, Hayes R, Michell MJ, Baum M. The mammographic parenchymal patterns of nulliparous women and women with a family history of breast cancer. Clin Radiol 1991; 43:385-8.
18. van Gils CH, Hendriks JH, Otten JD, Holland R, Verbeek AL. Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev 2000;9:105-11.
19. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes & Control 2000;11:653-62.
20. Adlercreutz H, Martin F, Pulkkinen M, et al. Intestinal metabolism of estrogens. J Clin Endocrinol & Metab 1976;43:497-505.
21. Adlercreutz H, Musey PI, Fotsis T, et al. Identification of lignans and phytoestrogens in urine of chimpanzees. Clin Chim Acta 1986;158: 147-54.
22. King RA. Daidzein conjugates are more bioavailable than genistein conjugates in rats. Am J Clin Nutr 1998;68:1496S-9S.
23. Bannwart C, Adlercreutz H, Wähälä K, et al. Identification of the phyto-oestrogen 3′,7-dihydroxyisoflavan, an isomer of equol, in human urine and cow's milk. Biomed Environ Mass Spectrom 1988; 17:1-6.
24. Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 2000; 10:127-35.
25. Kelly GE, Nelson C, Waring MA, Joannou GE, Reeder AY. Metabolites of dietary (soya) isoflavones in human urine. Clin Chim Acta 1993;223:9-22.
26. Hutchins AM, Slavin JL, Lampe JW. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc 1995;95:545-51.
27. Akaza H, Miyanaga N, Takashima N, et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002; 32:296-300.
28. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med 1995;208:40-3.
29. Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol, Biomarkers & Prev 2000;9:581-6.
30. McTiernan A, Ulrich CM, Yancey D, et al. The Physical Activity for Total Health (PATH) Study: rationale and design. Med Sci Sports Exerc 1999;31:1307-12.
31. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-96.
32. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. Automated analysis of mammographic densities. Phys Med Biol 1996;41:909-23.
33. Heinonen S, Wähälä K, Adlercreutz H. Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6′-OH-O-dma, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. Anal Biochem 1999;274:211-9.
34. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 2001;15:433-9.
35. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors α and β. Biol Pharm Bull 2001;24:351-6.
36. de Kleijn MJJ, van der Schouw YT, Wilson PWF, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: The Framingham Study. J Nutr 2001;131:1826-32.
37. Frankenfeld CL, Patterson RE, Homer NK, et al. Validation of a soy food-frequency questionnaire and evaluation of correlates of plasma isoflavone concentrations in postmenopausal women. Am J Clin Nutr 2003;77:674-80.
38. Järvenpää P, Kosunen T, Fotsis T, Adlercreutz, H. In vitro metabolism of estrogens by isolated intestinal micro-organisms and by human faecal microflora. J Steroid Biochem 1980;13:345-9.
39. Maskarinec G, Nagata C, Shimizu H, Kashiki Y. Comparison of mammographic densities and their determinants in women from Japan and Hawaii. Int J Cancer 2002;102:29-33.
40. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol, Biomarkers β Prev 2003;12:332-8.
41. Gapstur SM, Lopez P, Colangelo LA, Wolfman J, Van Hom L, Hendrick RE. Associations of breast cancer risk factors with breast density in Hispanic women. Cancer Epidemiol, Biomarkers β Prev 2003;12:1074-80.
42. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 1999;91:1404-8.